在软组织肉瘤中与PD1抑制剂结合使用抗血管原药的预测和动态签名:与IMMUNOSARC试验相关的相关研究

相关实验视频

Updated: Apr 13, 2026

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells
09:32

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Published on: February 8, 2018

14.5K

David S Moura1, Jesus M Lopez-Marti1, Iva Benesova2

  • 1Research Health Institute of Fundacion Jimenez Diaz (IIS/FJD; UAM), Madrid, Spain.

Clinical cancer research : an official journal of the American Association for Cancer Research
|September 16, 2024
PubMed
概括

在IMMUNOSARC试验中,sunitinib和nivolumab结合使用,在晚期肉瘤中增加CD8+T细胞密度. 一个分子签名预测了这种组合治疗的明显无进展生存结果.

更多相关视频

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.2K
A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies07:15

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies

Published on: July 28, 2020

9.5K

相关概念视频

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
6.5K